{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:20:18Z","timestamp":1760574018301,"version":"build-2065373602"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Clin. Diabetes Healthc."],"abstract":"<jats:p>Neonatal diabetes mellitus (NDM) is a rare cause of diabetes characterized by the presence of severe hyperglycemia typically diagnosed within the first six months of life. Among the main causes are activating variants in heterozygosity in the <jats:italic>KCNJ11<\/jats:italic> gene. Variants in this gene can lead to a spectrum of clinical manifestations, from transitory neonatal diabetes mellitus to DEND syndrome, the most severe form, characterized by developmental delay, epilepsy, neonatal diabetes, and muscle hypotonia. The disease may be present in a milder intermediate form named iDEND syndrome. Patients with <jats:italic>KCNJ11<\/jats:italic> variants may present with attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), developmental coordination disorder (DCD), and learning difficulties due to diminished intelligence quotient (IQ) and dyslexia. These patients can benefit from genetic counseling as most of them can switch from insulin to sulfonylurea treatment with good glycemic control and no severe side effects; besides, some studies report a neurological improvement after the treatment switch. In the present work, we reported a follow-up of a 24-year-old Brazilian male with DEND syndrome due to the <jats:italic>KCNJ11<\/jats:italic> c.754G&amp;gt;A; p.(Val252Met) variant. He was diagnosed with diabetes at 25 days of age and presented with bilateral hypoacusis in the first years of life. He started insulin at the diagnosis. However, the genetic diagnosis was made only at the age of 15 years, and he was switched from insulin to sulfonylurea. At 24 years of age, he presents with good glycemic control and reports no severe episodes of hypoglycemia or hyperglycemia. However, no neurological improvement was observed. This report highlights the potential benefits of switching to sulfonylurea treatment, even in patients with long-standing diagnoses of DEND syndrome, and underscores the importance of genetic diagnosis, as early initiation of sulfonylurea therapy may improve metabolic control and, in some cases, neurological outcomes.<\/jats:p>","DOI":"10.3389\/fcdhc.2025.1654037","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:41:50Z","timestamp":1760506910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: When genetic diagnosis comes late: lessons from a DEND syndrome patient successfully transitioned to sulfonylurea"],"prefix":"10.3389","volume":"6","author":[{"given":"Gabriella de Medeiros","family":"Abreu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritiele","family":"Bastos de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00edlia Chaves","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jardeson Lima","family":"da Cruz Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Snaider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Carolina Proen\u00e7a","family":"da Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaio Cezar Rodrigues","family":"Salum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f4nica Marques","family":"Zembrzuski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Antonio","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta Magalh\u00e3es","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Rodacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenita","family":"Zajdenverg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Luiz","family":"Luescher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliane Lopes","family":"Rosado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio","family":"Campos Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2213-8587(13)70059-7","article-title":"Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: A prospective cohort study","volume":"1","author":"Busiah","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0140-6736(15)60098-8","article-title":"The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: An international cohort study","volume":"2015","author":"De Franco","year":"9997","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-2-12","article-title":"Neonatal diabetes mellitus: A disease linked to multiple mechanisms","volume":"2","author":"Polak","year":"2007","journal-title":"Orphanet J. Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2015-0170","article-title":"Europe PMC Funders Group Neonatal diabetes in Ukraine: incidence, genetics, clinical phenotype and treatment","volume":"28","author":"Globa","year":"2016","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.02965.x","article-title":"Entities and frequency of neonatal diabetes: Data from the diabetes documentation and quality management system (DPV)","volume":"27","author":"Grulich-Henn","year":"2010","journal-title":"Diabetes Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-011-0331-8","article-title":"Minimal incidence of neonatal\/infancy onset diabetes in Italy is 1:90,000 live births","volume":"49","author":"Iafusco","year":"2012","journal-title":"Acta Diabetol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1416-6","article-title":"Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births","volume":"52","author":"Slingerland","year":"2009","journal-title":"Diabetologia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1399-5448.2009.00530.x","article-title":"Incidence of neonatal diabetes in Austria-calculation based on the Austrian Diabetes Register","volume":"11","author":"Wiedemann","year":"2010","journal-title":"Pediatr. Diabetes"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14312","article-title":"Neonatal diabetes mellitus around the world: Update 2024","volume":"15","author":"Barbetti","year":"2024","journal-title":"J. Diabetes Investig"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2020.54071","article-title":"Neonatal diabetes mellitus","volume":"8","author":"Beltrand","year":"2020","journal-title":"Front. Pediatr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.10.2713","article-title":"Permanent neonatal diabetes due to mutations in KCNJ11 encoding kir6.2: patient characteristics and initial response to sulfonylurea therapy","volume":"53","author":"Sagen","year":"2004","journal-title":"Diabetes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201629","article-title":"KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features","volume":"14","author":"Gloyn","year":"2006","journal-title":"Eur. J. Hum. Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032922","article-title":"Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit kir6.2 and permanent neonatal diabetes","volume":"350","author":"Gloyn","year":"2004","journal-title":"N Engl. J. Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30106-2","article-title":"Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study","volume":"6","author":"Bowman","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0351-y","article-title":"New insights into KATP channel gene mutations and neonatal diabetes mellitus","volume":"16","author":"Pipatpolkai","year":"2020","journal-title":"Nat. Rev. Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.9.2503","article-title":"Activating mutations in kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy","volume":"54","author":"Hattersley","year":"2005","journal-title":"Diabetes"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13135","article-title":"Psychiatric morbidity in children with KCNJ11 neonatal diabetes","volume":"33","author":"Bowman","year":"2016","journal-title":"Diabetes Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12428","article-title":"ADHD, learning difficulties and sleep disturbances associated with KCNJ11 -related neonatal diabetes","volume":"18","author":"Landmeier","year":"2017","journal-title":"Pediatr. Diabetes"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1060","article-title":"Cognitive, neurological, and behavioral features in adults with KCNJ11 neonatal diabetes","volume":"42","author":"Bowman","year":"2019","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2009.0165","article-title":"Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up","volume":"12","author":"Klupa","year":"2010","journal-title":"Diabetes Technol. Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2273-7","article-title":"No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes","volume":"54","author":"Iafusco","year":"2011","journal-title":"Diabetologia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2021.03.016","article-title":"Neonatal diabetes mellitus due to a new kcnj11 mutation-10 years of the patient\u2019s follow-up","volume":"63","author":"Je\u0161i\u0107","year":"2021","journal-title":"Turk J. Pediatr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3593-9","article-title":"Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes","volume":"58","author":"Thurber","year":"2015","journal-title":"Diabetologia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3921-8","article-title":"Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes","volume":"59","author":"Babiker","year":"2016","journal-title":"Diabetologia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055068","article-title":"Activating mutations in the ABCC8 gene in neonatal diabetes mellitus","volume":"355","author":"Babenko","year":"2006","journal-title":"N Engl. J. Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11892-019-1175-9","article-title":"Precision medicine: long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations","volume":"19","author":"Letourneau","year":"2019","journal-title":"Curr. Diabetes Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms13496","article-title":"Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic \u03b2-cells","volume":"7","author":"Brereton","year":"2016","journal-title":"Nat. Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13376","article-title":"Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses","volume":"23","author":"de Gouveia Buff Passone","year":"2022","journal-title":"Pediatr. Diabetes"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12447","article-title":"Molecular and clinical features of K ATP -channel neonatal diabetes mellitus in Japan","volume":"18","author":"Hashimoto","year":"2017","journal-title":"Pediatr. Diabetes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0837","article-title":"Sulfonylurea therapy benefits neurological and psychomotor functions in patients with neonatal diabetes owing to potassium channel mutations","volume":"38","author":"Beltrand","year":"2015","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13972_502","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31054","article-title":"Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM","volume":"6","author":"Martin","year":"2017","journal-title":"Elife"},{"key":"B33","article-title":"Permanent neonatal diabetes (DEND syndrome)","volume":"26","author":"Khan","year":"2016","journal-title":"J. Coll. Phys Surg. Pak"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13426","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: The diagnosis and management of monogenic diabetes in children and adolescents","volume":"23","author":"Greeley","year":"2022","journal-title":"Pediatr. Diabetes"},{"key":"B35","first-page":"1","volume-title":"Abordagem da pessoa jovem com diabetes 2019-2020 -Algoritmo para investiga\u00e7\u00e3o etiol\u00f3gica de pessoas jovens com diabetes","author":"Clannac","year":"2020"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2494","article-title":"Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons","volume":"99","author":"Carmody","year":"2014","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302010000800003","article-title":"Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene","volume":"54","author":"Vendramini","year":"2010","journal-title":"Arq Bras. Endocrinol. Metabol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1143736\/full","article-title":"Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants","volume":"14","author":"Mancioppi","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1145","article-title":"Diabetes presentation in infancy: high risk of diabetic ketoacidosis","volume":"40","author":"Letourneau","year":"2017","journal-title":"Diabetes Care"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0134476","DOI":"10.1371\/journal.pone.0134476","article-title":"Systemic administration of glibenclamide fails to achieve therapeutic levels in the brain and cerebrospinal fluid of rodents","volume":"10","author":"Lahmann","year":"2015","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-006-0112-3","article-title":"Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes","volume":"453","author":"Girard","year":"2006","journal-title":"Pflugers Arch. Eur. J. Physiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0227","article-title":"Amino acid properties may be useful in predicting clinical outcome in patients with Kir6.2 neonatal diabetes","volume":"167","author":"Fraser","year":"2012","journal-title":"Eur. J. Endocrinol"}],"container-title":["Frontiers in Clinical Diabetes and Healthcare"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2025.1654037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:41:51Z","timestamp":1760506911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2025.1654037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":42,"alternative-id":["10.3389\/fcdhc.2025.1654037"],"URL":"https:\/\/doi.org\/10.3389\/fcdhc.2025.1654037","relation":{},"ISSN":["2673-6616"],"issn-type":[{"value":"2673-6616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"1654037"}}